secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001390478-23-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start
--------------------------------------------------------------------------------

- Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.
- Phase 1 of GFH009 in AML completed; 94% of patients alive, durable remission >6 months; Phase 2a starting Q2.
- Phase 3 REGAL study of GPS in AML on track for interim analysis late 2023/early 2024; IDMC OK.
- 3D Medicines to trigger $13M milestone payments by Q3 2023 via REGAL participation in China.
- No licensing revenue in Q1 2023 (vs $1M in Q1 2022); R&D expenses rose to $7.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/0001390478-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/sls-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001390478-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer